Waylis Therap Drug Patent Portfolio
Waylis Therap owns 6 orange book drugs protected by 19 US patents with Aciphex having the least patent protection, holding only 2 patents. And Coreg Cr with maximum patent protection, holding 8 patents. Given below is the list of Waylis Therap's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8101209 | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles | 11 Mar, 2026 | Active |
US8101209 | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles | 11 Sep, 2025 | Active |
US7268156 | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment | 27 Dec, 2023 | Expired |
US7268156 | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment | 27 Jun, 2023 | Expired |
US6022562 | Medicinal and/or nutritional microcapsules for oral administration | 17 Apr, 2016 | Expired |
USRE40000 | Method of treatment for decreasing mortality resulting from congestive heart failure | 07 Dec, 2015 | Expired |
US5565467 | Androstenone derivative | 20 Nov, 2015 | Expired |
US6022562 | Medicinal and/or nutritional microcapsules for oral administration | 17 Oct, 2015 | Expired |
USRE40000 | Method of treatment for decreasing mortality resulting from congestive heart failure | 07 Jun, 2015 | Expired |
US6444673 | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it | 14 Aug, 2014 | Expired |
US6444673 | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it | 14 Feb, 2014 | Expired |
US5045552 | Pyridine derivatives having anti-ulcerative activity | 08 Nov, 2013 | Expired |
US5846976 | Androstenone derivative | 17 Sep, 2013 | Expired |
US5998427 | Androstenones | 17 Sep, 2013 | Expired |
US5045552 | Pyridine derivatives having anti-ulcerative activity | 08 May, 2013 | Expired |
US6864257 | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it | 02 Mar, 2013 | Expired |
US6864257 | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it | 30 Aug, 2012 | Expired |
US6319926 | Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it | 16 Jul, 2012 | Expired |
US7381724 | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same | 16 Jul, 2012 | Expired |
Latest Legal Activities on Waylis Therap's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Waylis Therap.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 21 Jun, 2023 | US8101209 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 14 Feb, 2019 | US7268156 |
Payment of Maintenance Fee, 8th Year, Large Entity | 29 Jan, 2019 | US8101209 (Litigated) |
Post Issue Communication - Certificate of Correction | 10 Apr, 2018 | US8101209 (Litigated) |
Change in Power of Attorney (May Include Associate POA)
Critical
| 27 Mar, 2018 | US8101209 (Litigated) |
Email Notification
Critical
| 27 Mar, 2018 | US8101209 (Litigated) |
Correspondence Address Change
Critical
| 26 Mar, 2018 | US8101209 (Litigated) |
Expire Patent
Critical
| 01 Jul, 2016 | US7381724 |
Expire Patent
Critical
| 08 Apr, 2013 | US6864257 |
Recordation of Patent Grant Mailed
Critical
| 24 Jan, 2012 | US8101209 (Litigated) |
Patent Issue Date Used in PTA Calculation
Critical
| 24 Jan, 2012 | US8101209 (Litigated) |
Issue Notification Mailed
Critical
| 04 Jan, 2012 | US8101209 (Litigated) |
Dispatch to FDC | 29 Dec, 2011 | US8101209 (Litigated) |
Application Is Considered Ready for Issue
Critical
| 20 Dec, 2011 | US8101209 (Litigated) |
Issue Fee Payment Verified
Critical
| 12 Dec, 2011 | US8101209 (Litigated) |
Waylis Therap's Family Patents
Waylis Therap Drug List
Given below is the complete list of Waylis Therap's drugs and the patents protecting them.
1. Aciphex
Aciphex is protected by 2 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US5045552
(Pediatric)
| Pyridine derivatives having anti-ulcerative activity |
08 Nov, 2013
(11 years ago)
| Expired |
US5045552 | Pyridine derivatives having anti-ulcerative activity |
08 May, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aciphex's drug page
2. Avodart
Avodart is protected by 3 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US5565467 | Androstenone derivative |
20 Nov, 2015
(9 years ago)
| Expired |
US5846976 | Androstenone derivative |
17 Sep, 2013
(11 years ago)
| Expired |
US5998427 | Androstenones |
17 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Avodart's drug page
3. Coreg
Coreg is protected by 2 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
USRE40000
(Pediatric)
| Method of treatment for decreasing mortality resulting from congestive heart failure |
07 Dec, 2015
(8 years ago)
| Expired |
USRE40000 | Method of treatment for decreasing mortality resulting from congestive heart failure |
07 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Coreg's drug page
4. Coreg Cr
Coreg Cr is protected by 8 patents, out of which 6 have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US8101209
(Pediatric)
| Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
11 Mar, 2026
(1 year, 3 months from now)
| Active |
US8101209 | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
11 Sep, 2025
(9 months from now)
| Active |
US7268156
(Pediatric)
| Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
27 Dec, 2023
(11 months ago)
| Expired |
US7268156 | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment |
27 Jun, 2023
(1 year, 5 months ago)
| Expired |
US6022562
(Pediatric)
| Medicinal and/or nutritional microcapsules for oral administration |
17 Apr, 2016
(8 years ago)
| Expired |
USRE40000
(Pediatric)
| Method of treatment for decreasing mortality resulting from congestive heart failure |
07 Dec, 2015
(8 years ago)
| Expired |
US6022562 | Medicinal and/or nutritional microcapsules for oral administration |
17 Oct, 2015
(9 years ago)
| Expired |
USRE40000 | Method of treatment for decreasing mortality resulting from congestive heart failure |
07 Jun, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Coreg Cr's drug page
5. Jalyn
Jalyn is protected by 3 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US5565467 | Androstenone derivative |
20 Nov, 2015
(9 years ago)
| Expired |
US5846976 | Androstenone derivative |
17 Sep, 2013
(11 years ago)
| Expired |
US5998427 | Androstenones |
17 Sep, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jalyn's drug page
Explore Our Curated Drug Screens
6. Lunesta
Lunesta is protected by 6 patents, out of which all have expired. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US6444673
(Pediatric)
| Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
14 Aug, 2014
(10 years ago)
| Expired |
US6444673 | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
14 Feb, 2014
(10 years ago)
| Expired |
US6864257
(Pediatric)
| Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
02 Mar, 2013
(11 years ago)
| Expired |
US6864257 | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
30 Aug, 2012
(12 years ago)
| Expired |
US6319926
(Pediatric)
| Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
16 Jul, 2012
(12 years ago)
| Expired |
US7381724
(Pediatric)
| Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same |
16 Jul, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lunesta's drug page